Cambridge-based genome analysis platform company Knome Inc. has pulled in $5 million of an expected $20 million equity funding round, federal documents [1] show.
The filing with the U.S. Securities and Exchange Commission indicated participation from one investor, though the backer was not identified specifically. Knome’s previous backers include French diagnostics firm bioMerieux, which put $5 million into an equity stake [2] in the Cambridge company in April 2010.
SOURCE [3]